Cortexyme, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The Company is focused on a infectious pathogen tied to neurodegeneration in humans and animal models. The Company’s lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer’s disease. COR388 is designed to target an upstream driver of multiple Alzheimer’s pathological pathways, including amyloid beta production, inflammation and neurodegeneration, in contrast to mechanisms of action targeting downstream effects, such as amyloid plaques and tau tangles.
Market Cap:1200M; Shares Outstanding:26.9M; Short Interest: 8.49%; Q3 2019(9/30/19): Cash 120M. Loss .86M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 47，no change
Shares hold: 5535.6k shares. no change
shares% hold: 20.61%，no change